Drug Type Biological products |
Synonyms IMBP150 |
Target |
Action modulators |
Mechanism PRDX5 modulators(peroxiredoxin 5 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatitis | Preclinical | United States | 01 Apr 2025 | |
Familial chylomicronaemia syndrome | Preclinical | United States | 10 Dec 2022 |